Clinical Trials Logo

Clinical Trial Summary

Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection


Clinical Trial Description

Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection. Yielding high levels of corticosteroid in the retinal and choroidal layers which was detectable for more than 3 months with limited exposure in the anterior segment. Triamcinolone acetonide is a synthetic corticosteroid formulated as an injectable suspension and has been evaluated in a number of trials to be 7.5 fold more potent anti-inflammatory than cortisone. Triamcinolone acetonide enhance tight junctions between endothelial cells thus reducing vessel leakage. It also has an angiostatic action by inhibition of vascular endothelial growth factor and has a useful effect on many inflammatory retinal diseases. The recommended dose of Triamcinolone acetonide injection is 4 mg/0.1 mL which was administrated in this study. The aim of this study was to assess the efficacy of suprachoroidal Triamcinolone acetonide injection (SCTA) in the management of Vogt-Koyanagi Harada's (VKH) multiple serous retinal detachment (RD) and evaluate best corrected visual acuity (BCVA), intraocular pressure(IOP) and central foveal thickness (CFT) by Optical Coherence Tomography (OCT) in patients diagnosed as VKH at ophthalmology clinic, Al Nil Hospital, Benha, EGYPT and Ebsar eye center, Benha, EGYPT. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031143
Study type Interventional
Source Benha University
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 1, 2020
Completion date August 24, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03399175 - Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease N/A
Completed NCT00407121 - Intravitreal Bevacizumab for Inflammatory Neovascular Membranes Phase 3